Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation.

ABSTRACT:

Objective

To compare the cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in patients with atrial fibrillation (AF).

Methods

Using standard methods, we created a Markov decision model based on the estimated cost of apixaban and data from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial and other trials of warfarin therapy for AF. We quantified the cost and quality-adjusted life expectancy resulting from apixaban 5 mg twice daily compared with those from warfarin therapy targeted to an international normalized ratio of 2-3. Our base case population was a cohort of 70-year-old patients with no contraindication to anticoagulation and a history of stroke or TIA from nonvalvular AF.

Results<

SUBMITTER: Kamel H 

PROVIDER: S-EPMC3525294 | biostudies-literature | 2012 Oct

REPOSITORIES: biostudies-literature